Mevalonate pathway and human cancers

Current Molecular Pharmacology

Volumn 9, Issue 3, 2016, Pages 77-85

  Bathaie, S Zahra ^a   Ashrafi, Mahboobeh ^b   Azizian, Mahshid ^a   Tamanoi, Fuyuhiko ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b SHIRAZ UNIVERSITY   (Iran)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROTEIN KINASE B; PROTEIN P53; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HIF1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER MODEL; CANCER PREVENTION; CANCER THERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASM; MULTIPLE MYELOMA; MUTATION; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; NEOPLASMS; PROTEIN PROCESSING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; MUTATION; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 85010644655     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467209666160112123205     Document Type: Article

References (88)

1. Goldstein, J. L.; Brown, M. S., Regulation of the mevalonate pathway. Nature 1990, 343, 425-430.
2. Cauley, J. A.; McTiernan, A.; Rodabough, R. J.; LaCroix, A.; Bauer, D. C.; Margolis, K. L.; Paskett, E. D.; Vitolins, M. Z.; Furberg, C. D.; Chlebowski, R. T., Statin use and breast cancer: prospective results from the Women's Health Initiative. J Nat. Cancer Inst. 2006, 98, 700-707.
3. Karp, I.; Behlouli, H.; LeLorier, J.; Pilote, L., Statins and cancer risk. Am. J. Medicine 2008, 121, 302-309.
4. Clendening, J. W.; Pandyra, A.; Boutros, P. C.; El Ghamrasni, S.; Khosravi, F.; Trentin, G. A.; Martirosyan, A.; Hakem, A.; Hakem, R.; Jurisica, I., Dysregulation of the mevalonate pathway promotes transformation. Proc. Nat. Acad. Sci. 2010, 107, 15051-15056.
5. Kidera, Y.; Tsubaki, M.; Yamazoe, Y.; Shoji, K.; Nakamura, H.; Ogaki, M.; Satou, T.; Itoh, T.; Isozaki, M.; Kaneko, J., Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coilcontaining protein kinase pathway. J. Exp. Clin. Cancer Res. 2010, 29, 127.
6. Koyuturk, M.; Ersoz, M.; Altiok, N., Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer letters 2007, 250, 220-228.
7. Johnson, J. M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P. M.; Armour, C. D.; Santos, R.; Schadt, E. E.; Stoughton, R.; Shoemaker, D. D., Genome-wide survey of human alternative premRNA splicing with exon junction microarrays. Science 2003, 302, 2141-2144.
8. Roy, M.; Kung, H.-J.; Ghosh, P. M., Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am. J. Cancer Res. 2011, 1, 542.
9. Nielsen, S. F.; Nordestgaard, B. G.; Bojesen, S. E., Statin use and reduced cancer-related mortality. New Eng. J. Med. 2012, 367, 1792-1802.
10. Lu, J.; Chan, L.; Fiji, H. D.; Dahl, R.; Kwon, O.; Tamanoi, F., In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol. Cancer Ther. 2009, 8, 1218-26.
11. Chan, L. N.; Fiji, H. D.; Watanabe, M.; Kwon, O.; Tamanoi, F., Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One 2011, 6, e26135.
12. Zimonjic, D. B.; Chan, L. N.; Tripathi, V.; Lu, J.; Kwon, O.; Popescu, N. C.; Lowy, D. R.; Tamanoi, F., In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer 2013, 13, 198.
13. Pelaia, G.; Gallelli, L.; Renda, T.; Fratto, D.; Falcone, D.; Caraglia, M.; Busceti, M.; Terracciano, R.; Vatrella, A.; Maselli, R., Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell proliferation 2012, 45, 557-565.
14. Palozza, P.; Colangelo, M.; Simone, R.; Catalano, A.; Boninsegna, A.; Lanza, P.; Monego, G.; Ranelletti, F. O., Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 2010, 31, 1813-1821.
15. Baskaran, G.; Salvamani, S.; Ahmad, S. A.; Shaharuddin, N. A.; Pattiram, P. D.; Shukor, M. Y., HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia. Drug Design, Devel. Therap. 2015, 9, 509.
16. Campbell, M. J.; Esserman, L. J.; Zhou, Y.; Shoemaker, M.; Lobo, M.; Borman, E.; Baehner, F.; Kumar, A. S.; Adduci, K.; Marx, C., Breast cancer growth prevention by statins. Cancer Res. 2006, 66, 8707-8714.
17. Kanugula, A. K.; Gollavilli, P. N.; Vasamsetti, S. B.; Karnewar, S.; Gopoju, R.; Ummanni, R.; Kotamraju, S., Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J. 2014, 281, 3719-3738.
18. Kotamraju, S.; Willams, C. L.; Kalyanaraman, B., Statin-induced breast cancer cell death: role of inducible nitric oxide and arginasedependent pathways. Cancer Res. 2007, 67, 7386-7394.
19. Kanugula, A. K.; Dhople, V. M.; Völker, U.; Ummanni, R.; Kotamraju, S., Fluvastatin Mediated Breast Cancer Cell Death: A Proteomic Approach to Identify Differentially Regulated Proteins in MDA-MB-231 Cells. PloS One 2014, 9, e108890.
20. Wang, Z.; Wu, Y.; Wang, H.; Zhang, Y.; Mei, L.; Fang, X.; Zhang, X.; Zhang, F.; Chen, H.; Liu, Y., Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Nat. Acad. Sci. 2014, 111, E89-E98.
21. Denoyelle, C.; Vasse, M.; Körner, M.; Mishal, Z.; Ganné, F.; Vannier, J.-P.; Soria, J.; Soria, C., Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001, 22, 1139-1148.
22. Hager, M. H.; Solomon, K. R.; Freeman, M. R., The role of cholesterol in prostate cancer. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9, 379-385.
23. Platz, E. A.; Leitzmann, M. F.; Visvanathan, K.; Rimm, E. B.; Stampfer, M. J.; Willett, W. C.; Giovannucci, E., Statin drugs andrisk of advanced prostate cancer. J. Nat. Cancer Inst. 2006, 98, 1819-1825.
24. Hamilton, R. J.; Banez, L. L.; Aronson, W. J.; Terris, M. K.; Platz, E. A.; Kane, C. J.; Presti, J. C.; Amling, C. L.; Freedland, S. J., Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer 2010, 116, 3389-3398.
25. Brown, M.; Hart, C.; Tawadros, T.; Ramani, V.; Sangar, V.; Lau, M.; Clarke, N., The differential effects of statins on the metastatic behaviour of prostate cancer. Brit. J. Cancer 2012, 106, 1689-1696.
26. Pandyra, A.; Mullen, P. J.; Kalkat, M.; Yu, R.; Pong, J. T.; Li, Z.; Trudel, S.; Lang, K. S.; Minden, M. D.; Schimmer, A. D., Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer Res. 2014, 74, 4772-4782.
27. Banker, D. E.; Mayer, S. J.; Li, H. Y.; Willman, C. L.; Appelbaum, F. R.; Zager, R. A., Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004, 104, 1816-1824.
28. Murphy, L. A.; Moore, T.; Nesnow, S., Propiconazole-enhanced hepatic cell proliferation is associated with dysregulation of the cholesterol biosynthesis pathway leading to activation of Erk1/2 through Ras farnesylation. Toxicol. Appl. Pharmacol. 2012, 260, 146-154.
29. Clendening, J.; Penn, L., Targeting tumor cell metabolism with statins. Oncogene 2012, 31, 4967-4978.
30. Qi, X.; Zheng, L.; Lee, K.; Kim, D.; Kim, C.; Cai, D.; Wu, Z.; Qin, J.; Yu, Y.; Kim, S., HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013, 4, e518.
31. Moreau, A. S.; Jia, X.; Patterson, C. J.; Roccaro, A. M.; Xu, L.; Sacco, A.; O’Connor, K.; Soumerai, J.; Ngo, H. T.; Hatjiharissi, E., The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Brit. J. Haematol. 2008, 142, 775-785.
32. Khurana, V.; Sheth, A.; Caldito, G.; Barkin, J. S., Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007, 34, 260-265.
33. Mohammed, A.; Qian, L.; Janakiram, N. B.; Lightfoot, S.; Steele, V. E.; Rao, C. V., Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int. J. Cancer 2012, 131, 1951-1962.
34. Zhong, C.; Fan, L.; Yao, F.; Shi, J.; Fang, W.; Zhao, H., HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumor Biology 2014, 35, 4123-4129.
35. Shi, J.; Zhu, J.; Zhao, H.; Zhong, C.; Xu, Z.; Yao, F., Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma. Tumor Biol. 2013, 34, 429-435.
36. Ogunwobi, O. O.; Beales, I. L., Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am. J. Gastroenterol. 2008, 103, 825-837.
37. Pavan, L. M. C., Rêgo, D. F., Elias, S. T., Canto, G. D. L., Guerra, E. N. S., In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review. PLOS One, 2015, 1-16. DOI:10.1371/journal.pone.0130476.
38. Yeganeh, B.; Wiechec, E.; Ande, S. R.; Sharma, P.; Moghadam, A. R.; Post, M.; Freed, D. H.; Hashemi, M.; Shojaei, S.; Zeki, A. A., Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol. Therapeut. 2014, 143, 87-110.
39. Gruenbacher, G.; Thurnher, M., Mevalonate metabolism in cancer. Cancer Lett. 2015, 356(2 Pt A), 192-6.
40. Pallottini, V.; Guantario, B.; Martini, C.; Totta, P.; Filippi, I.; Carraro, F.; Trentalance, A., Regulation of HMG-CoA reductase expression by hypoxia. J. Cellular Biochem. 2008, 104, 701-709.
41. Roitelman, J.; Olender, E. H.; Bar-Nun, S.; Dunn, W. A., Jr.; Simoni, R. D., Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. J. Cell Biol. 1992, 117, 959-73.
42. Gil, G.; Faust, J. R.; Chin, D. J.; Goldstein, J. L.; Brown, M. S., Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme. Cell 1985, 41, 249-258.
43. Liscum, L.; Finer-Moore, J.; Stroud, R.; Luskey, K.; Brown, M. S.; Goldstein, J. L., Domain structure of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum. J. Biol. Chem. 1985, 260, 522-530.
44. Brown, M. S.; Goldstein, J. L., Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980, 21, 505-517.
45. Sever, N.; Song, B.-L.; Yabe, D.; Goldstein, J. L.; Brown, M. S.; DeBose-Boyd, R. A., Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J. Biol. Chem. 2003, 278, 52479-52490.
46. Sever, N.; Yang, T.; Brown, M. S.; Goldstein, J. L.; DeBose-Boyd, R. A., Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol. cell 2003, 11, 25-33.
47. Tsai, Y. C.; Leichner, G. S.; Pearce, M. M.; Wilson, G. L.; Wojcikiewicz, R. J.; Roitelman, J.; Weissman, A. M., Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol. Biol. Cell 2012, 23, 4484-94.
48. Song, B.-L.; Sever, N.; DeBose-Boyd, R. A., Gp78, a membraneanchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Mol. cell 2005, 19, 829-840.
49. Lee, P. C.; Nguyen, A. D.; DeBose-Boyd, R. A., Mutations within the membrane domain of HMG-CoA reductase confer resistance to sterol-accelerated degradation. J. Lipid Res. 2007, 48, 318-327.
50. Goldstein, J. L.; DeBose-Boyd, R. A.; Brown, M. S., Protein sensors for membrane sterols. Cell 2006, 124, 35-46.
51. Horton, J. D.; Goldstein, J. L.; Brown, M. S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109, 1125-1131.
52. Vogelstein, B.; Lane, D.; Levine, A. J., Surfing the p53 network. Nature 2000, 408, 307-310.
53. Petitjean, A.; Achatz, M.; Borresen-Dale, A.; Hainaut, P.; Olivier, M., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26, 2157-2165.
54. Brosh, R.; Rotter, V., When mutants gain new powers: news from the mutant p53 field. Nature Rev. Cancer 2009, 9, 701-713.
55. Freed-Pastor, W. A.; Mizuno, H.; Zhao, X.; Langerød, A.; Moon, S.-H.; Rodriguez-Barrueco, R.; Barsotti, A.; Chicas, A.; Li, W.; Polotskaia, A., Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148, 244-258.
56. Oren, M.; Rotter, V., Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspect. Biol. 2010, 2, a001107.
57. Ginestier, C.; Charafe-Jauffret, E.; Birnbaum, D., p53 and cancer stem cells: the mevalonate connexion. Cell Cycle 2012, 11, 2583-2584.
58. Altomare, D. A.; Testa, J. R., Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24, 7455-7464.
59. Khwaja, A.; Rodriguez-Viciana, P.; Wennström, S.; Warne, P. H.; Downward, J., Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997, 16, 2783-2793.
60. Porstmann, T.; Griffiths, B.; Chung, Y.-L.; Delpuech, O.; Griffiths, J. R.; Downward, J.; Schulze, A., PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005, 24, 6465-6481.
61. Eberlé, D.; Hegarty, B.; Bossard, P.; Ferré, P.; Foufelle, F., SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86, 839-848.
62. Horton, J. D.; Shah, N. A.; Warrington, J. A.; Anderson, N. N.; Park, S. W.; Brown, M. S.; Goldstein, J. L., Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Nat. Acad. Sci. 2003, 100, 12027-12032.
63. Toth, J. I.; Datta, S.; Athanikar, J. N.; Freedman, L. P.; Osborne, T. F., Selective coactivator interactions in gene activation by SREBP-1a and-1c. Mol. Cel. Biol. 2004, 24, 8288-8300.
64. Bennett, M. K.; Toth, J. I.; Osborne, T. F., Selective association of sterol regulatory element-binding protein isoforms with target promoters in vivo. J. Biol. Chem. 2004, 279, 37360-37367.
65. Guo, D.; Bell, E. H.; Mischel, P.; Chakravarti, A., Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr. Pharm. Design 2014, 20, 2619.
66. Porstmann, T.; Santos, C. R.; Griffiths, B.; Cully, M.; Wu, M.; Leevers, S.; Griffiths, J. R.; Chung, Y.-L.; Schulze, A., SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Met. 2008, 8, 22, 224-236.
67. Sundqvist, A.; Bengoechea-Alonso, M. T.; Ye, X.; Lukiyanchuk, V.; Jin, J.; Harper, J. W.; Ericsson, J., Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF Fbw7. Cell Met. 2005, 1, 379-391.
68. Swinnen, J. V.; Brusselmans, K.; Verhoeven, G., Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Met. Care 2006, 9, 358-365.
69. Guo, D.; Prins, R. M.; Dang, J.; Kuga, D.; Iwanami, A.; Soto, H.; Lin, K. Y.; Huang, T. T.; Akhavan, D.; Hock, M. B., EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Anti-Lipogenic Therapy. Science Signaling 2009, 2, ra82.
70. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D., Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5, e8.
71. Ettinger, S. L.; Sobel, R.; Whitmore, T. G.; Akbari, M.; Bradley, D. R.; Gleave, M. E.; Nelson, C. C., Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004, 64, 2212-2221.
72. Heemers, H.; Maes, B.; Foufelle, F.; Heyns, W.; Verhoeven, G.; Swinnen, J. V., Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory elementbinding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol. 2001, 15, 1817-1828.
73. Bengoechea-Alonso, M. T.; Ericsson, J., Cdk1/cyclin B-mediated phosphorylation regulates SREBP1. FASEB J. 2007, 21, A290.
74. Hardie, D. G.; Ross, F. A.; Hawley, S. A., AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Rev. Mol. Cell Biol. 2012, 13, 251-262.
75. Jeon, S.-M.; Chandel, N. S.; Hay, N., AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485, 661-665.
76. Liu, L.; Ulbrich, J.; Müller, J.; Wüstefeld, T.; Aeberhard, L.; Kress, T. R.; Muthalagu, N.; Rycak, L.; Rudalska, R.; Moll, R., Deregulated MYC expression induces dependence upon AMPKrelated kinase 5. Nature 2012, 483, 608-612.
77. Mihaylova, M. M.; Shaw, R. J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biol. 2011, 13, 1016-1023.
78. Kuhajda, F., AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int. J. Obesity 2008, 32, S36-S41.
79. Motoshima, H.; Goldstein, B. J.; Igata, M.; Araki, E., AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 2006, 574, 63-71.
80. Li, Y.; Xu, S.; Mihaylova, M. M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J. Y.-J., AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabol. 2011, 13, 376-388.
81. Forcet, C.; Etienne-Manneville, S.; Gaude, H.; Fournier, L.; Debilly, S.; Salmi, M.; Baas, A.; Olschwang, S.; Clevers, H.; Billaud, M., Functional analysis of Peutz–Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Human Mol. Genet. 2005, 14, 1283-1292.
82. Xu, C.; Fillmore, C. M.; Koyama, S.; Wu, H.; Zhao, Y.; Chen, Z.; Herter-Sprie, G. S.; Akbay, E. A.; Tchaicha, J. H.; Altabef, A., Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25, 590-604.
83. Li, C.; Liu, V. W.; Chiu, P. M.; Yao, K.-M.; Ngan, H. Y.; Chan, D. W., Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Mol. Cancer 2014, 13, 49.
84. Riganti, C.; Doublier, S.; Costamagna, C.; Aldieri, E.; Pescarmona, G.; Ghigo, D.; Bosia, A., Activation of nuclear factor-kB pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol. Pharmacol. 2008, 74, 476-484.
85. Khanzada, U.; Pardo, O.; Meier, C.; Downward, J.; Seckl, M. a.; Arcaro, A., Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 2006, 25, 877-887.
86. Lee, J.; Lee, I.; Park, C.; Kang, W. K., Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 339, 748-54.
87. Wang, I. K.; Lin-Shiau, S. Y.; Lin, J. K., Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol. Toxicol., 2000, 86, 83-91.
88. Perez-Sala, D.; Mollinedo, F., Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994, 199, 1209-15.